bilaterals.org logo
bilaterals.org logo

medicines


As Modi visits US, what does the free trade pact mean for India’s pharma industry?
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
US farmers’ group says pharma, not dairy, is main obstacle to ratifying USMCA
The National Farmers Union says the new deal’s extended patent protection for new pharmaceuticals must be reduced so that less expensive generic versions of new drugs can be available to consumers sooner.
EU-US trade talks: milestone reached in mutual recognition on pharmaceuticals
The mutual recognition agreement for inspections of manufacturing sites for human medicines in their respective territories can make it faster and less costly for both sides to bring medicines to the market.
Old wine in new bottles: Keep TRIPS-plus provisions out of the RCEP FTA!
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement (FTA).
India protects drug, agriculture business at RCEP
Three harmful provisions concerning pharmaceuticals and agriculture which were part of the RCEP have been withdrawn.
Thai CSOs’ proposition against IP enforcement in the RCEP negotiation
FTA Watch would like to urge the Thai negotiation team for the RCEP to have a strong position to reject proposals on Intellectual Property Enforcement chapter.
NAFTA bill lets Trudeau cabinet wait and see what US Congress does Social Sharing
US Democrats fear higher drug prices, trying to change text of trade deal
Free trade can seriously damage your health
These practises open the door to Big Pharma companies and disastrous private health companies.
Will free trade make Africans sick?
African governments must act immediately to address the AfCFTA’s potential negative implications for Africans’ health.
2019: USTR takes aim at European countries over pharmaceutical pricing and reimbursement policies
In its latest report on foreign trade barriers, the USTR, prompted by the pharmaceutical industry, takes aim at the pharmaceutical pricing and reimbursement policies in the European Union.
PBO report shows that new NAFTA provisions threaten Pharmacare, says Council of Canadians
The Parliamentary Budget Officer (PBO) revealed that new intellectual property provisions in the Canada-United States-Mexico Agreement would cost Canadians as much as $169 million more per year for pharmaceutical drugs
Trump’s NAFTA 2.0 puts big pharma first, America second
The new version of NAFTA forbids the US Congress from curtailing Big Pharma’s patent monopolies on some of the world’s most expensive drugs.
How drug prices could derail new trade pact to replace NAFTA
Democrats in Congress contend that the new pact would force Americans to pay more for prescription drugs, and their argument has dimmed the outlook for one of Trump’s signature causes.
Provision that could raise drug costs emerges as key obstacle to NAFTA approval
Some Democrats in the US, like Canada’s generic drug industry, warn that the new biologics rule would keep drug prices high by requiring citizens to wait longer before they can get their hands on lower-cost similar drugs known as biosimilars.
More than 70 US health, consumer and other groups demand elimination of NAFTA 2.0 terms that would lock in high US medicine prices
In a letter to Congress, the groups demand that the pact’s giveaways to Big Pharma that would keep medicines unaffordable be removed before the pact is sent to Congress.
We can’t afford to let the new NAFTA drive up drug prices
NAFTA 2.0 would effectively tie the US Congress’ hands in the struggle against rising drug prices.
Comments on negotiating objectives for a US-Japan trade agreement
US drug manufacturers want Japan to provide 12 years of data protection for biologic medicine in upcoming trade talks. That would be four more years than Japan currently provides.
NAFTA 2.0: US-Mexico-Canada Agreement. Chapter 20: pharmaceutical related patent provisions
The Intellectual Property Chapter of the revised NAFTA, rebranded by the Trump Administration USMCA, includes provisions that threaten to undermine critical efforts to­wards affordable health care and medicine.
Indonesia and RCEP: Beware the public health risks
Proposals from Japan and South Korea would require patent law changes in several RCEP countries, including Indonesia.
PHA4: Neoliberal policies and corporate takeover are the cause of the world health crisis
Multinational corporations are suing countries for using generic versions of life saving medicines.